Aberrant psoriasis-associated gene expression was documented in LS versus NL at baseline, with gene expression normalization occurring as early as week 4 (and progressively sustained over 48 weeks) with guselkumab; the breadth and depth of gene expression normalization were more extensive with guselkumab than with ADA at all time points assessed. The gene discussed is ADA; the disease is psoriasis.